Pair of Chester County Companies Working on Potential COVID-19 Treatments

By
Trevena CEO Carrie Bourdow and Aclaris Therapeutics CEO Neal Walker.

Chesterbrook-based Trevena and Wayne-based Aclaris Therapeutics have joined the growing list of drug developers currently working on potential COVID-19 treatments, writes John George for the Philadelphia Business Journal.

Trevena is working with Imperial College London to evaluate the potential of one of its former drug candidates in patients with COVID-19.

Imperial College is sponsoring and funding a study of TRV027 – a drug candidate Trevena studied for acute decompensated heart failure – as a treatment for acute lung injury that contributes to acute respiratory distress syndrome in patients who contracted COVID-19.

“The COVID-19 infection causes things to be out of balance,” said Trevena CEO Carrie Bourdow. “The Imperial College study will look at how effectively TRV027 can restore that balance, repair damage to the lungs, and eliminate blood clots from developing.”

The study of the potential treatments is receiving additional support from the British Heart Foundation Centre for Research Excellence.

Meanwhile, Aclaris Therapeutics is supporting an investigator-initiated trial of ATI-450 – a drug it is developing on rheumatoid arthritis – for cytokine release syndrome.

The company is providing funding and clinical drug supply to research at the University of Kansas Medical Center, which is sponsoring the trial.

Read more in the Philadelphia Business Journal here.

You Might Also Like

MLH’s Center for Population Health Research Details Findings on COVID-19-Related Anxiety Levels

After First Affecting Chester County’s Densely Populated Areas, COVID-19 Hits Mushroom Country

Is Your Company Ready to Emerge from COVID-19? RKL Offers To-Dos and Tips for Successful Recovery Planning

Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Advertisement